Surgical Treatment of Atrial Fibrillation by Navaratnarajah, Manoraj et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Surgical Treatment of Atrial 
Fibrillation
Manoraj Navaratnarajah, Suvitesh Luthra and Sunil Ohri
Abstract
The concepts, techniques and evidence relating to surgical ablation of atrial 
fibrillation are discussed in detail. The historical background to surgical ablation is 
covered in brief, along with the electrophysiological basis underpinning its effective 
useage. The epidemiology of surgically treated atrial fibrillation and the current 
guidelines relating to its use are analysed. Safety aspects and perspectives on its 
ongoing future use are discussed. Modern surgical technologies and approaches are 
reviewed, along with the relevant advantages and disadvantages of each. The surgi-
cal techniques relating to left atrial appendage intervention are also reviewed, along 
with the relevant literature and evidence relating to reduction in thromboembolic 
risk and need for anticoagulation.
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1. Epidemiology of atrial fibrillation
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and 
remains a major cause of stroke, heart failure (HF), sudden death, and cardiovas-
cular morbidity. Importantly, with an ever-ageing population, the prevalence of AF 
is increasing, and predicted to rise steeply in the future [1]. AF impairs functional 
status, cognitive function and reduces the quality of life [2]. Age, sex, race, and geo-
graphical location, as well as other modifiable risk factors (diabetes, hypertension, 
lung disease, obesity and alcohol use) determine the prevalence of AF. The overall 
prevalence of AF is approximately 1%, but rises significantly with age. In those over 
75 years old it has been shown to be greater than 10%, and greater than 15% in those 
over 85 [3, 4].
As such, the proportion of patients presenting for cardiac surgery in AF, or with 
a history of AF is also expanding. AF detrimentally affects prognosis in patients 
with severe valvular heart disease [5], and those undergoing surgery or transcathe-
ter interventions for aortic or mitral valve disease, and in combination with valvular 
heart disease, increases thromboembolic risk significantly [6, 7]. As with congestive 
HF, valvular disease and AF share a dynamic interaction that sustain one another, 
driven by the detrimental effects of volume and pressure overload, maladaptive 
neurohumoral activation, cardiac fibrosis and a deleterious tachy-cardiomyopathy. 
Therefore, it is intuitive that immense attention has been, and continues to be 
focussed upon the potential likely benefits of surgical correction of AF, as part of 
both concomitant AND stand-alone procedures.
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1.1 Atrial fibrillation in surgical patients
The prevalence of pre-operative AF varies with the encountered cardiac pathol-
ogy, and this, together with surgical procedure type, influences the likelihood 
of concomitant surgical AF ablation. In the surgical population, the prevalence 
is greatly skewed towards mitral valve disease, because this pathology invokes 
the greatest degree of left atrial (LA) distension [8]. An AF prevalence of 30% 
is reported in mitral valve surgical patients, and only 14% and 6% in patients 
undergoing aortic valve or isolated coronary surgery, respectively [9]. Analysis of 
US registry data from the early 2000s showed that the prospect of concomitant AF 
ablation was greatest in mitral valve patients (~60%) and double that in aortic valve 
(~30%) and coronary artery bypass (~25%) surgical patients [10]. The chapter 
will focus upon the anatomical and physiological principles underlying surgical AF 
ablation, the technical and surgical aspects regarding specific anatomical lesion 
sets and their complications. Current evidence and guidelines supporting the use 
of surgical AF ablation, during both concomitant cardiac surgery and stand-alone 
surgery will also be reviewed.
2. Principles underlying surgical treatment of atrial fibrillation
A large variety of surgical strategies have evolved over past decades for the treat-
ment of AF. As such, standardisation of terminology is difficult and comparison 
of studies can prove impossible. Anti-arrhythmic procedures are divided into two 
broad categories: (A) isolation or (B) ablation procedures. Initial surgical proce-
dures were isolation procedures, aimed at confining the arrhythmia to a specific 
region of the heart [11]. Ablation was not carried out at this early time, as there was 
insufficient knowledge relating to the electrophysiological mechanisms driving 
AF. Isolation procedures such as LA isolation and the corridor operation will not be 
reviewed further in this chapter as they are irrelevant to current clinical practice.
Starting in the 1980s, several procedures were developed in an effort to treat 
AF, including LA isolation (A), corridor operation (B), and atrial transection (C) 
(Figure 1). The first attempt to surgically ablate AF was made via the atrial transection 
procedure in 1986 [12]. This procedure failed after 5 months in the 1 patient in which it 
was performed. Transection was based upon on the flawed belief that AF was caused 
by two macro-re-entrant circuits; one around the SVC and IVC orifices and one around 
the pulmonary veins and the orifice of the LA appendage (LAA). With improving 
knowledge of the mechanisms driving AF the MAZE procedure and pulmonary vein 
isolation (PVI) subsequently evolved, and formed the foundation of modern surgical 
treatment of AF. These two procedures form the main focus of this chapter.
2.1 The MAZE concept
The MAZE concept underlying the classical MAZE procedure is best encap-
sulated by the words of Dr James Cox—‘The cardinal feature of a classical MAZE 
procedure includes lines of conduction block that preclude macro-re-entry any-
where in either atrium while leaving both atria capable of activation by a sinus-
generated impulse. Components essential to achieving this include appropriate 
lesions in both atria, the absence of gaps that allow electrical activity to bypass an 
intended line of block, and the absence of alternate pathways by which impulses 
can reach the intended maze exit’. ‘The maze has one entrance site, one exit site and 
one true route between the entrance and exit’ [13] (Figure 2). It must be stressed 
that numerous surgical ablation strategies are now in existence that do not strictly 
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adhere to the MAZE concept described above, yet are described as ‘MAZE’ proce-
dures. The implications of utilising this generic umbrella term, when comparing 
studies and drawing conclusions from study outcomes must be appreciated.
2.2 Surgical ablation lesion sets
The first MAZE-I procedure was performed in 1987. It abolished AF and 
re-established sinus rhythm (SR) effectively. However, the MAZE-I was associ-
ated with chronotropic incompetence in approximately 30% of patients, and 
intra-atrial conduction delay resulting in loss of LA transport due to simultaneous 
LA and left ventricle (LV) contraction [13]. These two undesirable effects of the 
MAZE-I procedure, led to modifications in the lesion set thus creating the MAZE 
Figure 1. 
Schematic representation of AF isolation/ablation techniques. (A) His bundle ablation, (B) Left atrial 
isolation procedure, (C) Corridor procedure (D) Atrial transection procedure and (E) MAZE concept [13].
Figure 2. 
Schematic representation of the surgical MAZE concept [13].
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II procedure. The anterior-superior LA and right atrium (RA) lesions were repo-
sitioned in a more posterior location. The Maze II was performed in less than 15 
patients, due to extreme technical difficulty that required SVC transection above 
the RA to enhance LA exposure [13, 14]. The MAZE III included relocation of 
anterior lesion sets further posteriorly and a septal lesion to facilitate LA exposure, 
the latter being omitted subsequently in later iterations of the MAZE III. From 
1992 onwards the surgical cut-and sew MAZE-III procedure was performed 
through a median sternotomy, and the lesion pattern became the standard pattern 
for MAZE procedures. As the name implies, all cardiac lesions were created by cut-
ting the full thickness of the myocardium and then re-sewing the tissue together, 
thus inhibiting macro re-entry circuit conduction. It was not until 1997 when the 
original cut-and-sew MAZE-III procedure was replaced by cryosurgical MAZE-III 
procedure, where all surgical lesions were replaced by cryoablation lesions cre-
ated by a linear cryoprobe [13]. The MAZE III was then superseded by the first 
MAZE IV procedure in 2002. Lesion sets were essentially identical, with lesions in 
the MAZE IV performed using a combination of bipolar radiofrequency clamps 
and linear cryoprobes [15] (Figure 3). Improved speed of execution resulted in 
less patient morbidity during the MAZE IV, and this is now the gold standard 
procedure in AF ablation. Surgical AF ablation is most commonly applied as a 
concomitant procedure during valve or coronary revascularization operations, but 
also as a primary or stand-alone procedure. The frequency of surgical ablation and 
durable achievement of SR is increasing, represented mainly by the MAZE III/IV 
procedures.
3. Surgical ablation energy sources
Numerous energy sources have evolved over the past two decades to replace the 
traditional ‘cut and sew’ technique that aim to replicate transmural lesions, whilst 
enabling a less time-consuming yet equally effective approach. A fundamental 
pre-requisite for successful AF ablation, is complete transmurality and continuity 
bilaterally, and a correct lesion pattern.
Figure 3. 
Versions of the surgical MAZE procedure [13].
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3.1 Radiofrequency ablation
Radiofrequency ablation (RFA) acts by conducting an alternating electrical 
current through the myocardium. The energy of this electrical current disperses 
through myocardial tissue as heat, causing coagulative necrosis, creating an 
area of non-conducting myocardium. RFA employs an alternating current at 
350 kHz-1 MHz to heat tissue to 70–80°C for 1 min, creating a 3–6 mm lesion using 
unipolar or bipolar devices. Transmurality is indicated by electrical conductance 
and impedance monitoring. The efficacy of AF ablation during cardiac surgery 
using either unipolar [16–18], or bipolar ablation [19–21] technology, is well estab-
lished. Overall, success rates in restoring SR are over 60%, measured at a variety of 
time points ranging from 12 to 60 months post procedure. However, there is limited 
evidence to conclude whether bipolar RFA is more effective than unipolar RFA 
(Figure 4).
3.2 Cryoablation
Cryoablation works by using nitrous oxide as a cooling agent for 2 min at −60°C 
to produce a transmural lesion that can be visualised as an ‘iceball’.
Tissue injury results by creation of ice crystals within cells disrupting the cell 
function and electrical conductivity. In addition, microvascular disruption causes 
cell death. Several studies have proven the efficacy of concomitant cryoablation 
in the treatment of AF. Cryoablation during concomitant cardiac surgery achieves 
good rates of SR, ranging from 60 to 80% at a variety of time points ranging from 
12 to 60 months post procedure [22, 23] (Figure 4).
3.3 Microwave
Microwave ablation uses high-frequency electromagnetic radiation to induce 
oscillation of water molecules, and produces a well-demarcated lesion via thermal 
injury. Its main strength is the production of excellent epicardial lesions, thus 
promoting its use in minimally invasive techniques. A success rate ranging between 
65 and 85% is observed over a variable follow up period between 6 and 12 months 
[24]. Long term success rates remain unclear and evidence relating to microwave 
ablation efficacy is limited. Thus far, bipolar RFA ablation and cryoablation have 
demonstrated superiority in terms of freedom from AF, AF recurrence rates, 
and microwave ablation is currently considered less effective than other ablation 
modalities [25, 26].
Figure 4. 
Radiofrequency surgical ablation clamp (A) and cryoprobe (B) [105].
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3.4 Laser and ultrasound
Alternative energy sources being explored in AF ablation are that of laser and 
ultrasound. Laser ablation uses a monochromatic, phase coherent beam to cause 
heating and cellular destruction. Laser has shown efficacy in restoration of SR 
(>70%) in isolated procedures and during concomitant surgery [27]. However, 
currently, laser ablation has not gained approval for clinical use outside of trials 
due to limited evidence supporting its efficacy and safety [27]. Ultrasound, utilises 
high-frequency sound waves (2–20 MHz) emitted by piezoelectric crystals to cause 
thermal heating and disruption of cell membranes. It creates permanent transmural 
lesions when applied epicardially and is advantageous in that CPB is unnecessary, 
and ablation can be executed on a beating heart. Ultrasound lesions can also be 
delivered via a balloon catheter, allowing isolated PVI [28, 29]. Reasonable con-
version rates to SR have been demonstrated in isolated PVI for lone paroxysmal 
AF. However, due to frequent complications, such as atrio-oesophageal fistula, 
pericardial effusion and phrenic nerve palsy, use of ultrasound is not currently 
recommended, and its role in permanent AF is unproven [28, 29].
4. Surgical approaches for ablation
The MAZE IV can be performed either through a sternotomy or through a right 
mini thoracotomy. A combination of RFA and cryoablation is used to create the 
lesion set in the majority of cases. After gaining access to the chest both pulmonary 
veins are bluntly dissected, after initiating normothermic cardiopulmonary bypass 
(CPB). The patient is then cooled to 34°C and RA lesion set performed on a beating 
heart. A small purse-string suture at the base of the RA appendage allows one jaw of 
a RFA clamp to pass and create a lesion along the RA free wall (Figure 5). A vertical 
atriotomy extending from the intra-atrial septum up towards the atrioventricular 
Figure 5. 
Radiofrequency surgical ablation clamp performing right sided pulmonary vein isolation [106].
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groove near the free margin of the heart is made at least 2 cm from the free wall 
lesion. From the inferior aspect of the incision, the RFA clamp then creates ablation 
lesions extending to the SVC and down towards the IVC. A linear cryoprobe is used 
to create an endocardial ablation on the tricuspid annulus at the two o’clock posi-
tion. The cryoprobe is placed through the previously placed purse-string suture and 
an endocardial ablation is performed down to the 10 o’clock position on the tricus-
pid valve. When using a right mini-thoracotomy, the atriotomy is replaced by two 
additional purse-strings; one just above the intra-atrial septum midway between 
the SVC and IVC and one just next to the atrioventricular groove (Figure 6).
The LA lesion set is then performed under cardioplegic arrest. The LAA is 
amputated and the RFA clamp passed through to create a connecting lesion into 
the left superior pulmonary vein. The coronary sinus is marked with methylene 
blue at a point between the left and the right coronary arteries. A left atriotomy is 
performed and the posterior LA isolated using the RFA clamp both inferiorly and 
superiorly to connect the atriotomy to the previously made left pulmonary vein 
lesion (Figure 7). From the inferior part of the atriotomy an ablation lesion towards 
the mitral annulus is created. This lesion crosses the coronary sinus between the 
right coronary artery (RCA) and the circumflex artery. Cryoablation is then used 
to bridge the 2 cm gap from the end of the RFA lesion to the mitral valve annulus. 
Completion of the LA lesion set is carried out by cryoablating the coronary sinus in 
line with the isthmus lesion on the epicardial surface [30].
4.1 Thoracoscopic surgery
The MAZE IV is regarded as the gold standard surgical treatment for 
AF. However, the surgery although highly effective is quite invasive with related 
complications. Therefore, the totally thoracoscopic ablation procedure is gaining 
support as a minimally invasive alternative, and being performed both in a non-
hybrid or (staged) hybrid setting. A large variety of thoracoscopic approaches are 
now established and regarded as safe [31] (Figure 8). Totally, thoracoscopic LA 
‘MAZE’ procedures and PVI are described [32]. The procedures can be performed 
Figure 6. 
Right atrial lesion sets for MAZE IV procedure. (A) Majority of linear lesions are created using bipolar 
radiofrequency clamps, and blue shades represent cryoablation lesions placed at two points on the tricuspid 
annulus through direct vision or small purse-string sutures (red arrows). (B) Linear lesions also can be created 
with cryoablation if required for mini-thoracotomy. Right atrial lesion set consisting of an ablation line along 
the SVC and IVC, ablation along the RA free wall with line to tricuspid valve annulus [106].
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using three ports on both sides. On the right side, the pericardium is opened anterior 
to the phrenic nerve, followed by exploration of Waterston’s groove for subsequent 
positioning of the ablation device. Prior to PVI, ganglionic plexus location is 
Figure 8. 
Thoracoscopic PVI and LAA occlusion procedure. (A) Patient position and ports on left side. (B) Bipolar 
ablation clamp being placed around pulmonary vein hilum. (C) Clip being placed at the base of the left atrial 
appendage [107].
Figure 7. 
Left atrial lesion sets for MAZE IV procedure. (A) Majority of linear lesions are created with bipolar 
radiofrequency clamps. Blue shades represent cryoablation lesions at the mitral isthmus and left pulmonary veins 
(minimally invasive approach). (B) Linear lesions can also be created with cryoablation if required for mini-
thoracotomy. Left atrial lesion set consisting of bilateral PVI, pulmonary vein roof and floor connecting lesions, 
lesion from LSPV and amputated LAA, and lesion from inferior atriotomy to mitral valve annulus [106].
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performed using a transpolar pen and high frequency pacing. A positive plexus 
location is ablated for 20 s with the transpolar pen. High-frequency pacing is again 
performed to confirm successful ganglionic plexus ablation, and repeated if neces-
sary. After isolating the right pulmonary veins, some techniques include making a 
trigonum line. From the trigonum line, a separate lesion is made to the LAA. Blunt 
dissection around the PVs is performed using a dissector and PVI achieved by bipolar 
RFA ablation clamp. A minimum of three overlapping ablation lesions are performed 
at the antrum of the right PVs. Conduction block is confirmed, by the absence of 
PV potentials if AF is present; and by pacing if SR is present. Ablation is repeated if 
necessary. Both a roof line and a floor line are created with a linear pen, making up 
the box lesion. Left sided procedure is then carried out in a similar fashion; the peri-
cardium is opened posterior to the phrenic nerve and ligament of Marshall divided. 
The LAAO is amputated/occluded by a verity of techniques [32, 33].
However, review of 14 thoracoscopic studies shows that a wide variety of lesion 
sets are used, most frequently the trigone line, connecting the roof line with the left 
fibrous trigone; the LAA line, connecting the superior PVs with the LAA; and the 
bi-caval line [31]. Most described techniques employ bipolar RFA.
4.2 COBRA Fusion device
There are many suitable types of minimally invasive ablation devices on the 
market and the box lesion technique is used in most of them. One such novel device 
is the COBRA Fusion device. For this device the transverse and oblique sinuses are 
bluntly dissected, along with the layer of fat in the area of the interatrial groove 
and transverse sinus. A special introducer, with a magnetic tip, is inserted into 
each sinus to meet behind the heart and form a loop, and the COBRA Fusion 150 
(Estech, San Ramon, CA) ablation catheter is then connected to the introducer and 
pulled around the PVs (Figure 9).
Contact between atrial tissue and the catheter is then achieved using a unique 
suction device, with a target of suction of −500 mm Hg. The catheter uses unipolar 
and bipolar RFA to create lesions. The RFA is applied in 2 steps using temperature-
control using a setting of 70°C for 60 s. Following this first cycle, the catheter is 
moved circumferentially to complete the box lesion and a second cycle of energy, 
both mono- and bipolar is applied. The continuity of lesion is checked visually in a 
reachable area, and a third overlapping ablation lesion performed if the line of the 
box lesion appears non-continuous. This third ablation is usually needed between 
the right superior pulmonary vein and the right inferior pulmonary vein mainly in 
patients with a large LA. In addition to visual inspection of the lesion line, in patients 
Figure 9. 
COBRA Fusion surgical ablation device. A versatile and flexible design for epicardial ablation [105].
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in SR exit block can be routinely tested by pacing the right PVs and the adjacent pos-
terior LA, and another ablation performed if necessary. Of note however, successful 
box lesion isolation is only achievable in a minority of patients (<50%) [34].
5. Evidence and guidelines supporting surgical ablation
The majority of high-quality RCTs and meta-analyses of surgical ablation are 
weighted towards, but not confined to concomitant mitral procedures. As compared 
with patients in SR, those with AF tend to be older and to have worse baseline risk 
profiles. High baseline risk influences the decision not to perform concomitant abla-
tion, nevertheless, the majority of studies advocate that worse risk profiles are not 
a contraindication to surgical ablation [35]. It is established that surgical ablation 
for AF can be performed without additional operative risk of mortality or major 
morbidity [35, 36]. Indeed, recent US registry data suggests that surgical ablation 
is associated with reduced mortality in multiple valve populations [37]. Currently, 
US guidelines recommended concomitant ablation during mitral surgery (Class 1, 
Level A), AVR, isolated CABG, and AVR + CABG (Class1, Level B) [35].
Surgical ablation for symptomatic AF in the absence of structural heart disease, 
refractory to medical therapy or catheter-based therapies, receives a class II recom-
mendation as a primary stand-alone procedure (Level B). In addition, surgical abla-
tion for symptomatic persistent or long-standing AF in the absence of structural 
heart disease is deemed reasonable as a stand-alone procedure, using the MAZE III/
IV in comparison to PVI alone (Class IIA, Level B). Current literature shows that 
few technical restrictions are present opposing surgical ablation at the time of open 
atrial operations, and most studies agree that AF incidence is approximately halved, 
with this benefit maintained at 1 year [35, 37].
5.1 Safety and efficacy of surgical ablation
Clear direct demonstration of survival benefit following surgical ablation is 
not straight forward, due to heterogeneous study groups, follow-up periods and 
limited sample sizes. However, a clear link between restoration of SR and survival 
is verified in the literature. Regardless of survival benefit, long-term quality of 
life improvement following surgical ablation has been demonstrated by many, but 
not all studies [38, 39]. Surgical ablation does not abolish stroke risk, but has been 
associated with reduction in long-term stroke risk.
Surgically untreated AF correlates with increased morbidity and mortality 
following AVR [40], and freedom from AF is greater after concomitant surgical AF 
ablation [35]. Reluctance to open the atria during AVR and or CABG discourages 
full MAZE procedures, and less extensive/invasive epicardial ablative methods 
are often favoured. Therefore, the potential consequences of non-adherence to the 
strict MAZE principles outlined earlier, on outcomes must be appreciated. As such, 
SR recovery appears to be greater with bi-atrial MAZE procedures compared to PVI 
alone during CABG and or AVR [41, 42]. As with mitral surgery, performing the 
MAZE procedure during AVR and/or CABG surgery is also established to be safe 
[43]. SR restoration rates greater than 95% at 5 years have been reported following 
MAZE procedure and CABG, and concomitant PVI with CABG improves restora-
tion of SR in paroxysmal AF, with SR rates greater than 85% at 18 months [41, 44]. 
The efficacy of surgical ablation following AVR and or CABG has been shown to be 
at least equivalent to, if not superior to that following mitral surgery [35, 45].
The European guidelines also advocate concomitant AF ablation during cardiac 
surgery and agree its safety [46, 47]. A variety of Class II recommendations are 
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made [46]: (A) MAZE surgery, preferably bi-atrial, is recommended in symp-
tomatic patients undergoing cardiac surgery to improve symptoms attributable to 
AF, balancing the added risk of the procedure and the benefit of rhythm control 
therapy. (B) Concomitant bi-atrial MAZE or PVI may be considered in asymptom-
atic AF patients undergoing cardiac surgery [48].
In stand-alone surgery, MAZE procedure via mini-thoracotomy or thoracoscopic 
PVI have shown success rates ranging from 60 to 85% at 1 year, and success follow-
ing failed catheter ablation [49, 50]. European guidelines are positive, expressing 
that isolated epicardial PVI via minimally invasive surgery, OR MAZE surgery 
potentially using a minimally invasive approach should be considered, in patients 
with symptomatic refractory AF and failed catheter ablation.
Thoracoscopic ablation may be more effective in restoring SR than catheter abla-
tion in selected patients, although rate of complications is higher in the surgically 
group [51, 52]. With ever improving ablation technology and surgical instrumenta-
tion, the ability to perform larger lesion sets via a minimally invasive approach is 
likely to increase; and lead to expansion in the use of stand-alone AF surgery, and 
hybrid surgical-electrophysiological ablation. Data relating to hybrid procedures is 
encouraging, with success rates greater than 80% at 1 year [53, 54]. Long procedure 
times currently impede greater use, and more evidence is required to define optimal 
patient selection and long-term efficacy.
5.2 Limitations of evidence
The data discussed thus far is encouraging for surgical AF ablation. However, 
it is impossible to draw firm conclusions from the large amount of data relating to 
surgical AF ablation, with relation to survival, and definitive conclusions relating 
to efficacy, are hampered by the multi-level heterogeneity, with respect to lesion set 
performed, nature/duration of AF, patient population, follow up duration and defi-
nition/assessment of rhythm outcomes. Satisfactorily sized randomised trials, with 
standardised lesion sets, energy devices, uniform follow-up and rhythm assessment 
are needed to provide high level evidence; and are in progress.
A recent Cochrane review of 22 published trials concluded for patients with AF 
undergoing cardiac surgery, that concomitant AF surgery doubles the rate of free-
dom from AF/atrial arrhythmias while increasing the risk of permanent pacemaker 
(PPM) implantation. However, the authors described the available evidence as only 
moderate quality, and concluded that effects on mortality were uncertain. Significant 
heterogeneity was encountered amongst studies, but safety, stroke risk, and health-
related quality of life were not affected by concomitant surgical AF ablation. No 
benefit of one type of AF ablation over another was demonstrated [47]. All included 
studies were rated as being at a high risk of bias in at least one assessed domain. The 
recently published AMAZE randomised trial from Papworth, re-established that sur-
gical ablation increases the proportion of patients in SR at 12 months and 24 months: 
61.5% versus 46.9% and 58.5% versus 36.4%, respectively. The trialists concluded 
that surgical ablation was safe, but it did not improve quality of life or survival at 
2 years, a relatively early time point. There was no significant difference in stroke-
free survival, in serious adverse events, operative or overall survival, cardioversion 
or PPM implantation [55]. A major limitation of this study is that lesion sets were not 
standardised between surgeons. The longer-term results are awaited.
5.3 Pulmonary vein isolation versus MAZE procedure
The majority of surgical ablation studies in stand-alone AF have employed 
minimally invasive approaches; most frequently thoracoscopic off-pump RF PVI 
Epidemiology and Treatment of Atrial Fibrillation
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plus LAA amputation. Overall rates of freedom from AF of approximately 70–85% 
are reported at 12 months. Most studies, but not all, show conversion rates to be 
higher in paroxysmal AF than persistent AF when using PVI [56–58]. It is generally 
accepted that PVI is a reasonable treatment for paroxysmal AF with freedom rates 
of 70% reported at 5 years [59]. Direct randomised comparison between PVI and 
MAZE procedures is hard to find, with studies displaying marked heterogeneity.
In non-paroxysmal AF, PVI alone does not seem to be sufficient for maintenance 
of SR. In permanent AF patients with LA dilatation and valvular disease, additional 
lesions seem necessary. Systematic review of multiple studies shows that isolated 
PVI, has inferior efficacy to on-pump endocardial MAZE procedures, in patients 
with stand-alone AF, with a clear advantage of performing additional atrial lesions 
[60]. These effects are echoed in non-stand-alone AF. In a recent study of 260 
patients undergoing mitral valve surgery, with pre-dominantly non-paroxysmal AF, 
patients underwent surgical ablation with either PVI or biatrial MAZE, or mitral 
valve surgery alone. At, 12 months post-surgery, both ablation groups showed lower 
rates of AF than those undergoing mitral valve surgeries alone. A higher rate of AF 
was seen in the PVI group compared to biatrial MAZE (36% versus 23%). The aim of 
this study was primarily to assess a novel rhythm monitoring strategy post-surgery, 
and not lesion set comparison. The trial was not powered to detect a difference 
between the PVI and biatrial MAZE, but re-enforced other studies findings that a 
more complete lesion set may be superior in restoring SR, in patients undergoing 
mitral valve surgery [61]. In patients undergoing aortic or mitral valve surgery with 
permanent AF, PVI alone has been shown to be significantly inferior to PVI + addi-
tional LA lesions in restoration of SR; 25% versus 86% at 2 years [62]. This study 
along with others has demonstrated via electrophysiological mapping that complete 
continuous isolation of the pulmonary veins is often not achieved during surgi-
cal ablation. In a combined population of paroxysmal and persistent AF patients 
undergoing the Cox-Maze IV procedure, superior freedom from AF was obtained 
when patients received complete posterior LA isolation via a box-lesion, compared 
to a line between the inferior PVs only. Patients received a variety of concomitant 
procedures in this study including; CABG, mitral valve repair, tricuspid valve 
replacement, closure of patent foramen and aortic valve replacement [63]. Gillinov 
et al. showed in a randomised mitral valve surgical population with persistent or 
long-standing persistent AF that surgical ablation significantly improved freedom 
from AF at 1 year [64]. In a sub-set analysis they showed that PVI alone in com-
parison to biatrial lesion set creation appeared to show equivalent results; approxi-
mately 60% freedom from AF at 1 year. The authors have commented that the study 
was not adequately powered to show a difference between the two ablation sets, and 
emphasised the need for larger randomised studies to explore this question. This 
study has also received criticism for the relatively low percentage use of bipolar RFA 
in the PVI group (43%), relatively low success rate of freedom from AF at 1 year 
(60%), and the creation of biatrial lesion sets that did not strictly adhere to the true 
MAZE concept. The latter criticism, coupled to the factor that adequacy of PVI was 
confirmed electrophyisologically intra-operatively, may have led to the enhanced 
efficacy of PVI seen in this study, in this population.
5.4 Post-operative and peri-operative drug therapy
5.4.1 Anticoagulation
Following surgical AF ablation, full anticoagulation is common and reasonable 
until durable restoration of SR is proven, as long as safety criteria for anticoagula-
tion are met. Anticoagulation is usually continued until stable SR is documented by 
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the very least 24-h Holter monitoring. The time point at which monitoring should 
be conducted is debated, but is commonly at the 6 month follow up point, but many 
advocate rhythm monitoring at 1 year or beyond, and at multiple time points to 
capture late recurrence [35]. Sensible practice also recommends an echocardiogram 
before discontinuing anticoagulation to confirm adequate LA emptying.
5.4.2 Anti-arrhythmic therapy
There are currently no guideline recommendations for specific anti-arrhythmic 
drug therapy following surgical ablation. Randomised, controlled, prospective 
data relating to this question is lacking and is desirable. As discussed earlier there 
is marked heterogeneity between surgical ablation studies, and this extends to 
definition of AF recurrence, rhythm assessment protocols and also anti-arrhythmic 
therapy. Forming firm conclusions based on these studies relating to optimal drug 
therapy regimens, would be non-scientific and inappropriate. For example, in the 
recently performed AMAZE trial, amiodarone use in the post-operative period was 
standardised; however, beta blocker use was left up to the discretion of treating 
teams [55].
Overall, anti-arrhythmic drug therapy is commonly given for 8–12 weeks after 
catheter or surgical ablation to reduce early AF recurrence. In addition, a 3 month 
immediate ‘blanking period’, in which rhythm assessment is not performed, is 
usually employed. A recent controlled trial in a catheter ablation population showed 
that amiodarone halved early AF recurrences compared with placebo [65].
The ESC guidelines on the management of AF raise the concern that prospective 
studies are lacking with relation to anti-arrhythmic therapy post-catheter ablation, 
and available evidence is weak [46]. They conclude that better AF prevention is 
afforded after catheter ablation with anti-arrhythmic therapy, and this represents 
reasonable practice. Review of the literature relating to surgical ablation reveals 
that this sensible practice is employed almost universally. AF conversion is generally 
measured by the percent of patients off class I or III antiarrhythmic drugs and free 
of atrial tachyarrhythmia at 3, 6, 9, 12, and 24 months postoperatively. Recurrence 
is generally defined as any atrial tachyarrhythmia lasting longer than 30 s on a 24-h 
Holter monitor recording 6 months after surgical ablation. Amiodarone is the most 
commonly used drug for enhancing rhythm control post-surgical ablation, although 
routine use is not universal. Concomitant use of beta-blockade is common, although, 
not always routine. A multitude of data exists relating to the likely benefits of statins, 
amiodarone and various other drug regimens in the prevention of post-operative AF 
during routine cardiac surgery. To extrapolate this data to the surgical AF ablation 
population is reasonable. However, detailed, controlled studies are needed to define 
the precise short and long-term impact of drug therapy following surgical ablation 
procedures. Specific delineation of differences between different populations, e.g. 
CABG versus valvular disease groups, and differing drug regimens is necessary, but 
maybe challenging. The lack of definite evidence relating to drug therapy is reflected 
by the STS recommendation for multidisciplinary heart team assessment and long-
term follow up to optimise outcomes of surgical ablation for AF [35].
5.5 Animal studies
Safety and feasibility of surgical ablation technology and techniques was first 
explored in animal studies. The animal studies described here, stem from the efforts 
made to firstly (A) transition away from the traditional, technically demanding cut 
and sew MAZE procedure, as well as to (B) develop quicker, less invasive, +/− beat-
ing heart, surgical ablation techniques.
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The limitations of animal studies with relation to extrapolation of efficacy to 
humans must be borne in mind. There are known differences in atrial tissue and 
epicardial fat thickness, between the various used animal species and humans. 
Atrial thickness in the domestic pig is similar to that of the human, but levels of 
epicardial fat in the human are significantly greater, and so too is the thickness of 
diseased human atria [66]. In addition, electrophysiological differences with rela-
tion to impulse generation and AF pathophysiology, varies between animal species 
and humans. As with human studies, a multitude of devices and lesion sets have 
been employed, utilising both normal and chronically fibrillating hearts, precluding 
direct meaningful study comparison. As such, specific animal studies clearly dem-
onstrating efficacy of the MAZE procedure in restoration of SR are lacking. Overall, 
animal studies are best regarded as the preliminary studies that proved concept, 
safety and feasibility of surgical ablation in humans. They crucially provided the 
anatomical basis, technological characteristics/limitations, mechanistic insights and 
electrophysiological knowledge, which allowed informed ablation use in humans.
An early sheep study clearly established RFA to produce equally effective 
lesions to the cut and sew surgical technique. The RFA technique was shown to be 
significantly faster than incision technique with equivalent safety. In this 18 sheep, 
on-CPB endocardial ablation study, adequate lesion transmurality was demon-
strated using pacing at both acute and chronic (1 month) time points. The lesion 
set performed was similar but not identical to the classical MAZE procedure, and 
this study amongst others established RFA to be a simple, time saving alternative to 
surgical incisions during open heart MAZE procedures [67].
Examination of a variety of ablation technology devices, in various porcine 
beating heart ablation models, highlighted large variation in their ability to achieve 
transmurality [66]. The majority of devices failed to achieve full thickness lesions, a 
factor along with lesion continuity that has proven critical in preventing AF recur-
rence. Overall, the most consistently reliable devices for creating transmural lesions 
were demonstrated to be bipolar RFA clamps [68]. Although, highly reliable when 
performing PVI, use in creating intra-cardiac lesions during beating heart surgery 
is restricted to the right side, due to potential catastrophic effects of air embolism 
on the left. As such, the majority of beating heart animal studies study epicardial 
devices. Porcine studies amongst others, helped delineate the challenges facing 
surgical epicardial ablation. These included variability of atrial wall muscle thick-
ness and epicardial fat distribution, enhanced heat insulation by fat, and circulating 
intra-cavitary blood action as a potential heat sink [66]. These studies also identi-
fied the anatomical variation in reliability of transmurality achievement. Zones of 
difficulty, over Bachmann’s bundle, crista terminalis and at the mitral or tricuspid 
annuli, LAA and RAA were identified, along with zones of higher success around 
the pulmonary veins [69].
Acute and chronic studies using bipolar RF epicardial lesions have established 
that they do not significantly change pulmonary vein flow, nor cause significant 
acute or chronic pulmonary vein stenosis [68, 70]. In addition, pacing and epicardial 
mapping have both confirmed consistent, successful bidirectional isolation, with 
the real-time tissue conductance assessment, being able to reliably predict short and 
long term transmurality. Histologic examination re-enforced safety, showing safe 
discrete lesions without evidence of stricture, or aneurysm formation [70].
6. Complications of atrial fibrillation surgery
A disputed aspect surrounding surgical AF ablation is that of the relationship 
to PPM insertion. The rate of PPM insertion following surgical AF ablation varies 
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between 6% and 19%. The relationship is unclear, large meta-analyses comparing 
PPM insertion rates have demonstrated no significant increase in post-operative 
PPM requirement during concomitant AF ablation [48], yet a Cochrane review 
has demonstrated an increased requirement [47]. There is a presumed association 
between RA lesions and PPM implantation, and indeed a recent meta-analysis 
demonstrated that bi-atrial AF ablation surgery was associated with increased 
PPM insertion compared to isolated LA ablation [71]. Although not universal, most 
clinical studies show the increased need for PPM after AF ablation surgery to be 
driven mainly by sick sinus syndrome [9]. A proposed possible explanation is that 
of unmasking preoperative sinus node dysfunction. However, due to a multitude of 
confounding variables and lack of accurate reporting of preoperative data, it is not 
possible to precisely establish a causal mechanism.
As discussed earlier, despite increased CPB time and hospital length of stay, 
in the modern era, concomitant surgical AF ablation is regarded as safe, with no 
increase in mortality demonstrated [47, 72]. In addition, most studies demonstrate 
no increase in peri-operative stroke [47, 72]. Overall, the frequency of cardiac 
tamponade, pericardial effusion, myocardial infarction and re-operative bleeding 
does not appear to increase following concomitant surgical AF ablation [47, 72]. 
With relation to minimally invasive MAZE procedures and surgical AF ablation 
for stand-alone AF, safety is also acceptable. Minimally invasive epicardial surgical 
ablation is perceived to be safer than the endocardial MAZE procedure, because the 
former requires smaller incisions and does not require CPB. However, no statisti-
cally significant difference in mortality has been demonstrated [73]. Mortality rates 
of less than 0.5% are reported [60]. Results vary and are technique dependent, 
with some analyses showing lower re-operative bleeding rates and conversion to 
sternotomy with minimally invasive endocardial MAZE procedure [60], and others 
favouring minimally invasive epicardial surgical ablation without the use of CPB 
[73]. Similar conflicting results are noted with respect to the incidence of renal 
failure and hospital length of stay. As mentioned earlier, controlled studies are 
required to precisely delineate relationships between efficacy and safety of various 
minimally invasive techniques.
6.1 Predictors of AF recurrence following surgical ablation
Great efforts have been directed towards identifying predictors of AF recur-
rence, but have been hampered by the heterogeneity of studies with relation to 
ablation set, AF characteristics, rhythm assessment and pharmacological regi-
mens, amongst other variables. Risk factors for recurrence are broadly classified 
into pre-operative variables and intra-operative variables. Preoperative variables 
associated with AF recurrence include increasing LA diameter [15, 74, 75], age [76], 
and prolonged pre-operative duration of AF [75, 76]. In an excellent 280 patient 
prospective study, Damiano et al. showed in patients with both paroxysmal AF and 
persistent AF three risk factors for AF recurrence following the MAZE IV proce-
dure: increasing LA size, early post-operative AF and failure to anatomically isolate 
the entire posterior LA [15]. LA size of over 8 cm being has been shown by the same 
group to correlate with a >50% chance of AF recurrence. Gillinov et al. also showed 
in approximately 260 patients undergoing the cut and sew MAZE III procedure and 
mitral valve surgery, in a cohort of predominantly permanent AF patients, that risk 
factors for AF recurrence included longer duration of AF, larger LA diameter, older 
age, and higher left ventricular mass index [76]. In a systematic review involving 5200 
patients from 19 studies the authors showed that AF recurrence after surgical ablation 
was again most often predicted by LA size, duration of AF and age [75]. They also 
concluded that the innate heterogeneity of published data precluded a meta-analysis 
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for predictors of surgical ablation success, and highlighted the need for consistent 
and reliable outcome predictors, and a standardised system of measurement for 
clinical parameters.
Impact of intra-operative variables such as energy source and lesion set are a 
contested area. Again, heterogeneity of studies hinders comparison. Overall it is 
difficult to demonstrate that use of various energy sources affects AF recurrence 
rates. Similar long-term success rates have been observed with either uni- or bipolar 
RFA and cryoablation [77], yet both superiority of either bipolar RFA [78] or 
monopolar [79] has been shown in different studies. Although not certain, the bi-
atrial lesion set appears to display superiority to isolated LA lesion set in prevention 
of AF recurrence [78, 80]. In addition, modifiable risk factors such as hypertension, 
diabetes and smoking are implicated in surgical ablation failure [81].
7. Surgical versus catheter ablation
Catheter ablation is highly effective for the treatment of symptomatic, drug 
refractory AF. The reported efficacy for catheter ablation varies widely, although 
freedom from AF of up to 70% is reported, with worldwide registry data showing a 
procedural major adverse event rate of ~ 4.5%. Catheter ablation for the treatment 
of AF is currently recommended by guidelines as a second-line therapy in patients 
with paroxysmal and persistent AF after treatment with ≥1 antiarrhythmic drug 
has failed (Class I recommendation for paroxysmal AF, Class IIa for persistent AF, 
and Class IIb for long-stranding persistent). Most randomised controlled trials 
(RCTs) of drug therapy versus catheter ablation have studied patients with pre-
served left ventricular function [82]. Recently, RCTs have also shown the benefit 
of rhythm control with catheter ablation over medical therapy for AF associated 
with heart failure [83]. A recent meta-analysis examining six RCTs confirmed these 
findings demonstrating catheter ablation to be superior to medical therapy for AF 
in patients with HF, resulting in greater improvement in LVEF, quality of life and 
functional status, with a definite survival benefit [84]. Results from the recent 
CABANA trial also echo these positive catheter ablation effects in HF patients [85]. 
Although variable, a pooled freedom from AF of 71% was seen in this analysis.
There is not much direct comparison of surgical ablation versus catheter abla-
tion in the literature. The FAST study included 124 patients with drug–refractory 
AF, LA dilatation and hypertension or failed prior catheter ablation. Patients were 
randomised to either catheter ablation or thoracoscopic surgical ablation. Catheter 
ablation consisted of linear antral PVI and optional additional lines. Surgical abla-
tion consisted of bipolar RF PVI, ganglionated plexi ablation, and LAA excision 
with optional additional lines. Freedom from AF was superior for surgical ablation at 
12 months (36.5% versus 65.6%), but this was at the expense of greater rate of compli-
cations, driven mainly by pneumothorax, major bleeding, and the need for PPM [52]. 
A meta-analysis of eight studies showed that thoracoscopic surgical ablation showed 
significantly greater freedom from AF at 12-months compared to catheter ablation 
(78.4 versus 53%), with a reduced requirement for repeat ablation [86]. This superior-
ity was maintained in paroxysmal and persistent AF subgroups. However, again, com-
plications were shown to be considerably higher in the surgical group, driven mainly 
by pleural effusion and pneumothorax. Limitations of the data were the retrospective 
nature of some of the included studies and the heterogeneity of patients involved.
The superior efficacy demonstrated by surgical intervention is postulated to be 
due to several factors [86]. The ablation lesion set employed with surgery is gener-
ally much more extensive including PVI, but also targeted epicardial ganglionic 
plexi, LAA excision and additional LA lines. The importance of ganglionic plexi 
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and the LAA in perpetuating AF re-entrant circuits is well recognised [87, 88]. In 
catheter ablation relative inadequate treatment may be occurring, as additional 
ablation lines are often not performed, with endocardial lesions consisting of PVI 
using wide-area antrum ablation alone. In addition, a better ability of surgical 
technology to create adequate transmural lesions may underlie its superior efficacy.
Debate continues regarding the optimal lesion set for stand-alone surgical abla-
tion. Specifically, the comparative efficacy of strategies of PVI versus extended LA 
lesion sets, or MAZE IV approach remains unknown, and requires further study. 
Further controlled studies are also needed to delineate the apparent supremacy of 
surgical ablation over catheter ablation. However, concerns relating to the higher 
rate of complications and prolonged length of stay of the more invasive surgical 
approach currently impede adoption of its use on a broader scale. The majority of 
these complications are non-severe and managed conservatively, and whether such 
this level of apprehension is justified is unclear. Surgical ablation is increasingly 
performed as a stand-alone procedure and with improving technology and surgical 
skill its use is likely to expand with time, either on its own or as part of a hybrid 
electrophysiological approach.
7.1 Electrophysiological mapping
Unfortunately electrophysiological evaluation after bipolar RF PV isolation has 
been scarcely performed. Only a small minority of surgical ablation studies have per-
formed detailed intra-operative or peri-operative validation of ablation sets [64]. It is 
clear that confirmation of adequacy of ablation transmurality and continuity impacts 
upon surgical ablation efficacy and subsequent AF recurrence rate [89, 90]. Several 
factors oppose routine electrophysiological validation of ablation including; (A) 
technically challenging to adequately pace in between instead of on the performed 
ablation lines, (B) time consuming to perform correctly; with epicardial lesions, at 
least 20 min between PV isolation and endocardial validation is needed and (C) pre-
cise delineation of the border between conducting and non-conducting tissue at the 
distal sleeve of the PV is sometimes difficult to perform without complex mapping 
techniques. In its simplest form following PVI, entrance block is defined as failure to 
capture the PVs during pacing from the LA, and exit block can be defined by failure 
to capture the LA, when pacing from the PVs distal to the RF lesions.
Following minimally invasive PVI, recurrence rates as high as 40% have been 
seen despite intra-operative electrophysiological validation. Repeat electrophysi-
ological investigation shows the vast majority are due to PV reconnection. In 
mini-MAZE [90] and total thoracoscopic procedures [91] intra-operative electro-
physiological validation has been associated with higher success rates of 84% and 
93% at 24 and 12 months respectively, in mixed AF populations. Sophisticated 3D 
electrophysiological mapping again showed recurrence was secondary to PV gaps in 
50% of patients, with ectopic foci in LAA, peri-mitral LA roof flutter in the remain-
der. Post-operative recurrence is generally amenable to catheter ablation, with good 
intermediate-term success [92]. These findings re-enforce the growing belief that 
the hybrid ablation approach, either immediate or staged will produce the best long 
term ablation outcomes. Augmented success rates with a combined staged hybrid 
approach have been achieved, with a required catheter-based ‘touch up’ rate of 
approximately 20% following surgical intervention [93].
The predominant factor in AF recurrence post-ablation is PV reconnection or 
incomplete isolation. Several reasons for the gaps around the PVI ring are impli-
cated: (A) clamp application failure over the roof of the superior PVs, (B) incom-
plete clamping at the bottom of inferior PV, (C) clamp application failure at the 
antral side of the PV due to the long distance between the superior and inferior PVs, 
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or accessory PVs and (D) increasing LA size. Multiple reasons for improper clamp 
application and diminished RFA effect are also cited including (A) angulation of 
clamps rather than perpendicular placement; (B) blood within the PVs limiting tis-
sue involution between the clamps on beating hearts; (C) clamp movement during 
beating heart ablation; (D) the cooling effect of circulating blood and (E) anatomic 
factors such as atrial folds, ridges and variable myocardial thickness.
Improving the quality of the lesion set, will undoubtedly improve durability and 
success of surgical ablation; and better intra-operative electrophysiological mapping 
strategies represents a good target to focus upon. It is clear that simple entrance and 
exit block confirmation has a false negative rate, most likely related to tissue oedema, 
trauma and ischaemia, and the optimum universal mapping technique and strategy 
is not established. Randomised controlled studies with detailed electrophysiological 
interrogation follow up, are needed to identify this technique and strategy and then 
standardise their application, and improve surgical lesion set creation.
8. Left atrial appendage intervention
LAA exclusion or occlusion LAAO can be safely performed. Growing inter-
est in LAA intervention has been driven by the observation that 90% of thrombi 
in non-valvular AF (NVAF) and 60% of those in valvular AF develop in the 
LAA. LAAO by surgical excision or device occlusion is postulated to reduce the risk 
of stroke, peripheral thromboemboli, and necessity for oral anticoagulants. Surgical 
techniques available to isolate the LAA include LAA excision with amputation, 
or occlusion which can be performed endocardially or epicardially. LAAO can be 
performed using an implantable device or without. Non-device approaches include 
surgical two-layer closure with running or mattress sutures, stapling and excision, 
and placement of surgical purse-strings or clips around the LAA base. Success is 
dependent on total LAA excision or isolation. Any residual stump of the LAA >1 cm 
in length, or gap with associated blood flow is thrombogenic [94]. LAA exclusion 
however has been inconsistent in terms of techniques, rates of complete exclusion, 
and thus adoption. Studies comparing internal ligation, external staple excision 
and surgical excision show that complete LAA elimination should not be assumed. 
Initial stump-free elimination can deteriorate with time, and a residual stump can 
be immediately present, emphasising the importance of immediate and late echo-
cardiographic interrogation of LAA intervention [95].
8.1 Left atrial appendage devices
A variety of devices exist. The most widely used endocardial device is the 
Watchman device, which is a percutaneously delivered polyester fabric on a nitinol 
frame (Figure 10). The Lariat device utilises a combined percutaneous and epicar-
dial approach to deliver a lasso around the appendage guided by an intraluminal 
magnet tip. The AtriClip is made of two polyester-covered parallel tubes with 
nitinol springs (Figure 11). The AtriClip is a self-closing clamp placed epicardially 
at the base of the LAA to exclude blood flow. In general, endocardial devices remain 
in contact with intracardiac blood, and therefore anticoagulation for 2 months is 
recommended following implantation, making them less attractive for patients with 
contraindications to anticoagulation. Endocardial devices also fail to lie properly in 
LAAs with unfavourable morphologies.
The strongest evidence supporting reduction of stroke risk and potentially the 
elimination of anticoagulation with LAAO comes from the large, multi-centre RCT, 
PROTECT AF. This study used the percutaneous Watchman LAA device. After 
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3.8 years of follow-up in patients with NVAF at elevated risk for stroke, percutane-
ous LAA closure met criteria for both non-inferiority and superiority, compared 
with warfarin, for preventing the combined outcome of stroke, systemic embolism, 
and cardiovascular death, as well as superiority for cardiovascular and all-cause 
mortality [96].
In a large meta-analysis reviewing over 2400 patients, the efficacy of LAA 
closure compared to warfarin in 2 RCTS, PREVENT AF and the PREVAIL trial was 
analysed. At a mean follow up of 2.7 years in patients with NVAF at increased risk 
for stroke or bleeding, LAA intervention improved rates of haemorrhagic stroke, 
cardiovascular/unexplained death, and non-procedural bleeding. These positive 
effects were offset by an increase in ischemic strokes, mainly peri-procedural. 
All-cause stroke or systemic embolism was similar between both strategies. 
This analysis emphasised a non-inferiority of LAAO to warfarin use; with LAA 
intervention beneficial effects seeming to be underpinned by the circumvention 
of anticoagulation-related morbidity and mortality, as opposed to prevention of 
thromboembolism [97]. However, these positive results could not be automatically 
extrapolated to surgical LAA intervention.
8.2 Left atrial appendage intervention during cardiac surgery
Retrospective analysis of over 10,000 patients undergoing surgical AF 
ablation with and without concomitant surgical LAAO, showed only 37% 
underwent LAAO. Concomitant LAAO significantly reduced readmission for 
Figure 10. 
The watchman left atrial appendage occlusion device. A percutaneously delivered polyester fabric device on a 
nitinol frame [108].
Figure 11. 
Left atrial appendage occlusion AtriClip device. Parallel titanium crossbars apply adequate pressure without 
crushing or damaging tissue [105].
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thromboembolism and all-cause mortality. The additional procedure was demon-
strated to be safe, but the important differentiation between technique of LAAO, 
nature of AF and echocardiographic parameters between groups was not made [98]. 
In an updated meta-analysis examining over 3600 patients from 7 studies a signifi-
cant reduction in stroke, and all-cause mortality was demonstrated in patients with 
AF undergoing LAAO during cardiac surgery, compared to those not undergoing 
LAAO. Techniques of suture ligation and stapling were utilised, and a variety of 
post-operative anticoagulation regimens and follow up periods [99].
The best clinical evidence for LAAO devices exists for the AtriClip device 
(AtriCure). It is the most commonly used surgical device with over 100,000 
recorded implants worldwide. It is applied with concomitant cardiac operations 
as well as in isolated thoracoscopic procedures safety and efficacy of the AtriClip 
device was evaluated in the EXCLUDE trial. In 70 patients undergoing primary 
cardiac operations AtriClip, demonstrated 95% successful exclusion with 98% 
complete LAA exclusion on CT at 3 months [100]. Success was defined as occlusion 
with no residual neck >1 cm and no leaks or migration. The upcoming results of the 
large (n = 4700) multicentre, randomised LAAOS III trial will aid in clarifying the 
long-term outcomes of LAAO in AF patients undergoing cardiac surgery [101].
The practice of prophylactic LAA closure in patients without AF undergoing car-
diac surgery does not appear to be effective. A recent large scale, propensity-matched 
analysis of prophylactic LAA closure, showed that this was associated with early 
increase in post-operative AF and no decrease in stroke risk or mortality [102]. The 
ATLAS trial is now randomising patients without documented AF, at high risk for 
the developing post-operative AF undergoing elective cardiac surgery; to LAA exclu-
sion with the AtriClip or no concomitant AtriClip placement. The LAAOS III and 
ATLAS trials are the largest trials investigating efficacy of LAA occlusion for stroke 
prevention at the time of cardiac surgery; and their results are eagerly awaited.
Currently, the US and the European guidelines state that it is reasonable to, or 
consideration should be given to, performing LAA intervention in conjunction with 
surgical AF ablation and during cardiac surgery, for longitudinal thromboembolic 
morbidity prevention (Class II, Level C/B). European guidelines also say it is 
reasonable to perform isolated LAA intervention in patients in AF with contraindi-
cation to anticoagulation.
8.3 Left atrial appendage intervention and anticoagulation
There is large variability in anticoagulation strategies post LAAO and surgical 
ablation alone with mixed-use of warfarin, NOACs and single and dual antiplatelet 
agents. The optimal anticoagulation therapy is still a matter of debate. Decisions 
regarding anticoagulation and imaging should be made and tailored to patient 
and procedural characteristics. The decision is often straight forward, in patients 
with a contraindication to anticoagulation referred for LAA exclusion. However, 
for patients without contraindications to anticoagulation, the decision is less 
simple. The Zurich group has shown in 36 patients receiving AtriClip, with a mean 
CHA2DS2-VASc score of 3.7, that only one transient ischemic attack (TIA) occurred 
after >1200 day follow up, with no strokes [98]. Three patients received anticoagu-
lation. They have also shown a reduction in stroke risk in 291 patients with a mean 
CHA2DS2-VASc score of 3.1, receiving AtriClip during concomitant surgery cardiac 
surgery [103]. Patients that did not receive anticoagulation after LAA exclusion had 
a relative risk reduction of 87.5% in stroke, with an observed ischaemic stroke-rate 
of 0.5/100 patient-years compared with an expected rate in a group of patients with 
similar CHA2DS2-VASc scores of 4.0/100 patient-years. No evidence of reperfusion 
or residual stump was observed [104].
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Evidence regarding anticoagulation management post-operatively is not robust, 
and further well-powered long-term evidence is needed to confidently guide 
anticoagulation management in patients receiving the AtriClip but have no con-
traindications to anticoagulation. Currently, the European guidelines recommend 
that patients undergoing LAA intervention remain on anticoagulation (Class 1). 
However, the view that anticoagulation is not needed after AtriClip application is 
also held by many, with single anti-platelet agent thought to be sufficient.
9. Summary and conclusions
Surgical AF ablation has evolved over the past few decades and is now safe, and 
associated with minimal morbidity. The gold standard lesion set remains that of the 
MAZE IV, yet ‘lesser’ lesion sets, are gaining favour within the minimally invasive, 
hybrid and non-hybrid treatment setting, for treatment of NVAF. It is clear that 
surgical ablation displays beneficial effects, but the supportive evidence is not of 
the highest quality, and high quality RCTS with standardised ablation sets, AF 
criteria and defined rhythm assessment outcomes are needed. New studies need 
to precisely define and quantify the role of surgical ablation on rhythm, survival, 
symptoms, thromboembolic risk, and the exact relationship with specific target 
AF populations. Similarly, high level evidence is needed to quantify the impact of 
LAA intervention on thromboembolic risk in AF. Identification of the optimal LAA 
intervention, together with clear guidance on anticoagulation is necessary.
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